Worldwide sales of products for the prevention of surgical adhesions in humans were estimated at greater than $1.2 billion USD in 2014. There are numerous potential indications in the human market which include the prevention of surgical tendon adhesions, spinal adhesions, cranial adhesions, and abdominal adhesions. The market for the prevention of surgical adhesions is growing at the rate of 20% per year due to increasing physician awareness and improving diagnostic techniques.
Annually, 27 million surgical procedures are performed in the US and Europe where the patient is at risk for the formation of surgical adhesions. Those patients are ideal candidates to receive prophylactic treatment using a product that effectively prevents the formation of surgical adhesions. In addition, there are more than 1.7 million surgeries performed in the US and Europe to lyse adhesions that have resulted in clinical complications such as infertility or small bowel obstruction annually. Patients undergoing surgery to lyse adhesions are likely to form adhesions again and are ideal candidates to receive prophylactic treatment to prevent the re-formation of surgical adhesions. The market is not limited to the United States and Europe; for example, 20 million surgical procedures are performed annually in China in which the patient is at risk for the formation of surgical adhesions.
The following surgeons have joined ARC's Clinical Advisory Board: - Dr. Rudy De Wilde, PhD, ScD, MD.Dr. De Wilde is the Director of Ob/Gyn at Pius Hospital in Germany and a key opinion leader and principal investigator of adhesion clinical studies.- Dr. Brian Kwon, MD, FRCSC, PhD.Dr. Kwon is a surgeon-scientist who is an Associate Professor in the Department of Orthopaedics (UBC), the Associate Director, Clinical Research, for ICORD and the Associate Scientific Director of the Rick Hansen Institute. - Dr. Jian (James) Ye, MD, MSc, FRCSC. Dr. Ye is a cardiovascular surgeon, director of Clinical Research at St. Paul's Hospital and a Clinical Professor of Surgery at UBC.
ARC successfully developed an animal spine (laminectomy) surgical adhesion model and showed compelling efficacy of fucoidan in preventing the formation of spinal adhesions in the spine model.
Fucoidan significantly reduced the formation of cardiac adhesions in an animal cardiac model.
ARC entered into an exclusive distribution and supply agreement with Vedco, Inc. for PERIDAN in the U.S. equine veterinary market.
ARC successfully developed an animalmodel for cardiac surgical adhesions.